UBS analyst Ashwani Verma lowered the firm’s price target on Legend Biotech (LEGN) to $54 from $60 and keeps a Buy rating on the shares. UBS continue to see upside to Legend Biotech stock, but the upside is based on modest growth in Q2, with an acceleration in the second half of 2025, the analyst tells investors in a research note. The stock may continue to be range-bound unless there is a material step-up in the revenue profile of Carvykti, UBS contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Promising Outlook for Legend Biotech’s CARVYKTI: Buy Rating Affirmed by Mitchell Kapoor
- Legend Biotech’s CAR T Cell Therapies See FDA REMS Removal and EMA Label Update
- Legend Biotech Concludes Successful 2025 Annual General Meeting
- Legend Biotech Unveils Updated Corporate Presentation Highlighting CAR-T Success
- Legend Biotech Appoints Peter Salovey as Lead Independent Director